段文凯

古塞奇尤（Guselkumab），是一种针对IL-23的p19亚基的全人源化免疫球蛋白G1λ单克隆抗体，通过特异性结合IL-23的p19亚基，阻断IL-23信号传导，抑制TH17细胞分化和增殖，减少促炎细胞因子产生，从而减轻银屑病症状。与抗TNF药物和乌司奴单抗相比，古塞奇尤在治疗成人银屑病方面表现出更高的疗效。早期应用古塞奇尤可能对疾病的转归起到积极作用，短病程患者更可能成为临床超反应者。同时古塞奇尤对掌趾脓疱病、泛发型脓疱型银屑病也有较好的疗效，对关节型银屑病表现出有利的获益-风险特征。古塞奇尤的常见不良反应轻微且可控，严重不良反应发生率低。在临床试验中，未发现绝对禁忌症，但活动性结核病、存在慢性感染或有反复感染史的患者应慎用。

IL-23p19抗体；古塞奇尤；白细胞介素23；银屑病

[1] Raharja,Antony,et al.“Psoriasis:A Brief Overview.”Clinical Medicine(London,England),vol.21,no.3,1 May 2021,pp.170-173. [2] Michalek,I.M.,et al.“A Systematic Review of Worldwide Epidemiology of Psoriasis.”Journal of the European Academy of Dermatology and Venereology,vol.31,no.2,30 Aug.2016,pp.205–212. [3] Armstrong,April W.,and Charlotte Read.“Pathophysiology,Clinical Presentation,and Treatment of Psoriasis.”JAMA,vol.323,no.19,19 May 2020,p.1945,jamanetwork.com/journals/jama/article-abstract/2766169. [4] Zhou,Li,et al.“A Non-Clinical Comparative Study of IL-23 Antibodies in Psoriasis.”MAbs,vol.13,no.1,1 Jan.2021. [5] Wechter T,Cline A,Feldman SR.Targeting p19 as a treatment option for psoriasis:an evidence-based review of uselkumab[J].Ther Clin Risk Manag,2018,14:1489-1497. [6] Mehta,Heena,et al.“Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs.Secukinumab.”Journal of Investigative Dermatology,vol.141,no.7,July 2021,pp.1707-1718.e9. [7] Sawyer,Laura M.,et al.“Assessing the Relative Efficacy of Interleukin-17 and Interleukin-23 Targeted Treatments for Moderate-To- Severe Plaque Psoriasis:A Systematic Review and Network Meta-Analysis of PASI Response.”PLOS ONE,vol.14,no.8,14 Aug. 2019,p.e0220868. [8] Knut Schäkel,et al.“Early Disease Intervention with Guselkumab in Psoriasis Leads to a Higher Rate of Stable Complete Skin Clearance(“Clinical Super Response”):Week 28 Results from the Ongoing Phase IIIb Randomized,Double-Blind,Parallel-Group, GUIDE Study.”J Eur Acad Dermatol Venereol,vol.2023 Oct;37(10):2016-2027.,no.37(10),1 June 2023. [9] Eyerich,Kilian,et al.“IL-23 Blockade with Guselkumab Potentially Modifies Psoriasis Pathogenesis:Rationale and Study Protocol of a Phase 3b,Randomised,Double-Blind,Multicentre Study in Participants with Moderate-To-Severe Plaque-Type Psoriasis(GUIDE).”BMJ Open,vol.11,no.9,Sept.2021,p.e049822. [10] Reich,Kristian,et al.“Guselkumab versus Secukinumab for the Treatment of Moderate-To-Severe Psoriasis(ECLIPSE):Results from a Phase 3,Randomised Controlled Trial.”The Lancet,vol.394,no.10201,Sept.2019,pp.831-839. [11] Terui,Tadashi,et al.“Efficacy and Safety of Guselkumab in Japanese Patients with Palmoplantar Pustulosis.”JAMA Dermatology,vol. 155,no.10,1 Oct.2019,p.1153. [12] Miyachi,Hideaki,et al.“Treatments and Outcomes of Generalized Pustular Psoriasis:A Cohort of 1516 Patients in a Nationwide Inpatient Database in Japan.”Journal of the American Academy of Dermatology,vol.86,no.6,1 June 2022,pp.1266-1274,pubmed.ncbi. nlm.nih.gov/34116101/. [13] Tada,Yayoi,et al.“Safety and Effectiveness of Guselkumab in Japanese Patients with Psoriasis:20-Week Interim Analysis of a Postmarketing Surveillance Study.”The Journal of Dermatology,vol.51,no.6,15 May 2024,pp.779-790. [14] Deodhar,Atul,et al.“Guselkumab in Patients with Active Psoriatic Arthritis Who Were Biologic-Naive or Had Previously Received TNFαInhibitor Treatment(DISCOVER-1):A Double-Blind,Randomised,Placebo-Controlled Phase 3 Trial.”The Lancet,vol.395,no.10230, Apr.2020,pp.1115-1125. [15] Yiu,Zenas Z.N.,et al.“Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab,Ixekizumab, Secukinumab,Ustekinumab,and Adalimumab in Patients with Psoriasis.”JAMA Dermatology,vol.2022;158(10),6 July 2022. [16] Crowley,John,et al.“Safety of Selective IL‐23p19 Inhibitors for the Treatment of Psoriasis.”J Eur Acad Dermatol Venereol,vol.33, no.9,27 June 2019,pp.1676-1684. [17] Duncan,James Robert,et al.“Safety of Guselkumab in Hepatitis B Virus Infection.”Dermatology Online Journal,vol.25,no.10,2019. [18] Reich K,Griffiths CEM,Gordon KB,et al.Maintenance of clini-cal response and consistent safety profile with up to three years of continuous treatment with guselkumab:results from the VOYAGE 1 and VOYAGE 2 trials[J].J Am Acad Dermatol,2019.[pub-lished online ahead of print]. [19] Hussar,Daniel A.;Kotova,Mariya.(2018).Safinamide mesylate,Brodalumab,Guselkumab,and Abaloparatide.Journal of the American Pharmacists Association,58(1),123-127. [20] Amandine Dernoncourt,et al.“Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken during Pregnancy by Women with Autoimmune Diseases:Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®).”BioDrugs,vol.37,no.1,19 Nov.2022,pp.73-87.

点击下载PDF